SE9604296D0 - New pharmaceutical formulation of polypeptides - Google Patents

New pharmaceutical formulation of polypeptides

Info

Publication number
SE9604296D0
SE9604296D0 SE9604296A SE9604296A SE9604296D0 SE 9604296 D0 SE9604296 D0 SE 9604296D0 SE 9604296 A SE9604296 A SE 9604296A SE 9604296 A SE9604296 A SE 9604296A SE 9604296 D0 SE9604296 D0 SE 9604296D0
Authority
SE
Sweden
Prior art keywords
lipid
pharmaceutical formulation
new pharmaceutical
polypeptides
relates
Prior art date
Application number
SE9604296A
Other languages
Swedish (sv)
Inventor
Thomas Berglindh
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9604296A priority Critical patent/SE9604296D0/en
Publication of SE9604296D0 publication Critical patent/SE9604296D0/en
Priority to PCT/SE1997/001927 priority patent/WO1998022135A1/en
Priority to AU51418/98A priority patent/AU5141898A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to a new pharmaceutical formulation comprising a lipid aggregate of a negatively charged lipid or lipid mixture and at least one antigenic, native or recombinant polypeptide which constitute a Helicobacter pylori antigen, and optionally a pharmaceutically acceptable carrier. More specifically the invention relates to a lipid aggregate comprising a surface-exposed antigen with an approximate molecular weight of 29 kDa. Furthermore the invention provides a formulation of a nucleic acid molecule coding for the said polypeptide. The new formulations, which are useful as vaccine formulations, elicit a protective immune response against H. pylori infections, and said vaccine formulations are suitable for both therapeutic and prophylatic use.
SE9604296A 1996-11-22 1996-11-22 New pharmaceutical formulation of polypeptides SE9604296D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
SE9604296A SE9604296D0 (en) 1996-11-22 1996-11-22 New pharmaceutical formulation of polypeptides
PCT/SE1997/001927 WO1998022135A1 (en) 1996-11-22 1997-11-18 Pharmaceutical lipid aggregate with helicobacter pylori antigen and negatively charged lipid
AU51418/98A AU5141898A (en) 1996-11-22 1997-11-18 Pharmaceutical lipid aggregate with helicobacter pylori antigen and negatively charged lipid

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9604296A SE9604296D0 (en) 1996-11-22 1996-11-22 New pharmaceutical formulation of polypeptides

Publications (1)

Publication Number Publication Date
SE9604296D0 true SE9604296D0 (en) 1996-11-22

Family

ID=20404716

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9604296A SE9604296D0 (en) 1996-11-22 1996-11-22 New pharmaceutical formulation of polypeptides

Country Status (3)

Country Link
AU (1) AU5141898A (en)
SE (1) SE9604296D0 (en)
WO (1) WO1998022135A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP2204186B1 (en) 1999-02-17 2016-04-06 CSL Limited Immunogenic complexes and methods relating thereto
GB0008879D0 (en) * 2000-04-12 2000-05-31 Astrazeneca Ab Polypeptide delivery system
GB0008877D0 (en) * 2000-04-12 2000-05-31 Astrazeneca Ab Polypeptide delivery system
GB0010371D0 (en) * 2000-04-29 2000-06-14 Astrazeneca Ab Helicobacter pylori antigens
EP3936116A1 (en) 2007-12-28 2022-01-12 Takeda Pharmaceutical Company Limited Rrecombinant vwf containing formulations
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
US20120135039A1 (en) * 2008-10-08 2012-05-31 Aldwell Frank E Oral Vaccines for Producing Mucosal Immunity
PT2349314E (en) 2008-10-21 2013-05-28 Baxter Int Lyophilized recombinant vwf formulations
WO2017102779A1 (en) * 2015-12-14 2017-06-22 Technische Universität München Helicobacter pylori vaccines

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643574A (en) * 1993-10-04 1997-07-01 Albany Medical College Protein- or peptide-cochleate vaccines and methods of immunizing using the same

Also Published As

Publication number Publication date
AU5141898A (en) 1998-06-10
WO1998022135A1 (en) 1998-05-28

Similar Documents

Publication Publication Date Title
MY119003A (en) Bacterial antigens and vaccine compositions
TR200100936T2 (en) Therapeutic vaccination
IS4518A (en) New vaccine formulation
AR006999A1 (en) AN IMMUNOGENIC, THERAPEUTIC OR PROPHYLACTIC COMPOSITION, INCLUDING AN ISOLATED POLYPEPTIDE, AN ISOLATED ANTIBODY THAT IS LINKED TO SUCH A POLYPEPTIDE AND A VACCINE THAT UNDERSTANDS IT.
NZ503763A (en) Antigenic compositions and vaccines comprising a high molecular weight (HMW) protein of Clamydia for therapeutic and prophylactic use
EP1712628A3 (en) Compounds and methods for immunotherapy and diagnosis of tuberculosis
KR890701758A (en) Analogs of Bordetella exotoxin subunits derived from recombinant DNA and vaccines comprising the same
EP2172551A3 (en) Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
SE9604296D0 (en) New pharmaceutical formulation of polypeptides
Rask et al. Mucosal and systemic antibody responses after peroral or intranasal immunization: Effects of conjugation to enterotoxin B subunits and/or of co‐administration with free toxin as adjuvant
CA2014033A1 (en) Compositions and treatments for pneumonia in animals
BR9812240A (en) Altered g protein or rsv polypeptide, use of it, nucleic acid molecule encoding an altered g protein or rsv polypeptide, nucleic acid construction, recombinant host cell, processes of producing an altered g protein or rsv polypeptide immunogenic composition , to induce an immune response in a vertebrate, to inhibit the induction of disease increase after vaccination and subsequent infection of a vertebrate with rsv and to immunize a vertebrate against rsv, vaccine composition, vaccine, and, composition immunogenic
DK0892054T3 (en) Clostridium perfringens vaccine
EA200100395A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING DNA FRAGMENTS ENCODING ANTIGENIC PROTEIN COATING ANTI-ANTITROTHAL EFFECT
US8647636B2 (en) Low antigen-dose immunization utilizing overlapping peptides for maximizing T-helper cell 1 (Th1) immunity against a pathogen
WO1993014206A3 (en) Synthetic peptides for a rubella vaccine
WO1999051188A3 (en) A polypeptide comprising the amino acid of an n-terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof
ES2079851T3 (en) USE OF IL-4 TO IMPROVE THE IMMUNE RESPONSE AGAINST IMMUNOGEN IN VACCINES.
PE20010237A1 (en) GENE DERIVED FROM LAWSONIA AND OmpH POLYPEPTIDES, PEPTIDES AND RELATED PROTEINS AND THEIR USES
SE9604322D0 (en) Bacterial antigens and vaccine compositions II
HK1025220A1 (en) Novel saponin compositions and uses thereof
DE69928947D1 (en) MORAXELLA CATARRHALIS BASB034 POLYPEPTIDES AND USES THEREOF
BR0112141A (en) Peptides, polypeptide, composition, use of a peptide or polypeptide, and, antibody
BR9712968A (en) Genes encoding mycobacterial proteins associated with cell ligand and cell registration and use of these
NZ331889A (en) Trypanosomatids histones for use as an antigen against trypanosomatic infection, including diagnostic tests, pharmaceutical compositions and vaccines of these antigens